We demonstrated that administration of selegiline, a registered, irreversible MAO-B inhibitor anti-Parkinson medication with propargylamine moiety in its chemical structure, has attenuated the kanamycin-induced hearing loss (an AGIHL) in mice. The gene discussed is MAOB; the disease is hearing loss disorder.